Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?

Myriad Genetics (MYGN) is focusing on oncology and prenatal testing expansion, despite a 79% stock drop in the past year and a Zacks Rank #3 (Hold) rating. The company's GeneSight test lost UnitedHealthcare coverage, causing a 20% year-over-year revenue decline; however, Myriad has delivered four consecutive earnings beats and maintains a strong solvency position with $92 million in cash and no short-term debt. Strategic priorities include collaborations, AI integration, and new product launches like Precise MRD, aiming for long-term growth despite macroeconomic pressures and a projected 3.1% revenue fall in 2025.

Analysis

Myriad Genetics (MYGN) presents a mixed financial profile, characterized by a severe 79% decline in its stock value over the past year, significantly underperforming both its industry and the S&P 500. This downturn is exacerbated by the loss of UnitedHealthcare coverage for its GeneSight test, which commenced in the first half of 2025 and contributed to a 20% year-over-year reduction in GeneSight revenues during the first quarter. Consequently, Zacks Consensus Estimates project a 3.1% decrease in total revenues for 2025 to $811.7 million, and the 2025 earnings estimate has recently been revised downwards. Despite these headwinds and a Zacks Rank #3 (Hold), MYGN has demonstrated operational resilience by surpassing earnings estimates in the last four trailing quarters with an average surprise of 210% and maintains a strong solvency position, reporting $92 million in cash and cash equivalents with no short-term debt at the end of Q1 2025. The company is actively pursuing growth through strategic initiatives in oncology and women's health, evidenced by an 11% year-over-year growth in MyRisk testing volume and an 11% increase in prenatal testing revenues in Q1 2025. Key future drivers include the planned launch of its Precise MRD test in the first half of 2026, a collaboration with Gabbi initiated in February 2025, the integration of PATHOMIQ’s AI technology, and new patents for its MRD technology. However, ongoing macroeconomic pressures, including inflation and potential U.S. tariffs, continue to pose risks to profitability.

Key Decisions for Investors

• Investors should exercise caution due to the significant stock underperformance and the material revenue impact from the GeneSight coverage loss, carefully weighing these against the company's reported earnings beats and strong solvency.
• Monitor Myriad Genetics' ability to offset revenue declines through growth in its oncology and women's health segments, particularly tracking the market adoption and sales trajectory of new products like MyRisk, Prequel, and the forthcoming Precise MRD test.
• Evaluate the company's progress on strategic collaborations, AI integration, and the impact of updated NCCN guidelines on Prolaris test volumes, as these are crucial for its long-term growth strategy amid persistent macroeconomic challenges.